Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Dyne Therapeutics (DYN) announced the appointments of Vikram Ranade, PhD, as chief business officer, CBO, and Ranjan Batra, PhD, as chief ...

Washburn University’s football team will be looking for a new quarterback to lead the huddle this upcoming season.

Insiders who acquired US$1.06m worth of Dyne Therapeutics, Inc.'s ( NASDAQ:DYN ) stock at an average price of US$33.04... Shares of several biotech and biopharma names are under pressure on Monday ...

WALTHAM, Mass. - Dyne Therapeutics, Inc. (NASDAQ:DYN), a biotechnology company focusing on neuromuscular diseases with a market capitalization of $845 million, announced significant changes to its ...

WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...

WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...